Galapagos NV taps Landmark Bio for CAR-T therapy production
Landmark Bio has entered into a pivotal strategic manufacturing agreement with Galapagos NV, signaling a notable advance in the field of genomic medicines. This multi-year agreement positions Landmark Bio to produce clinical trial batches for Galapagos’ CAR T-cell therapies, with an emphasis on hematology-oncology, within the biotech hub of the Boston metropolitan area. Accelerating CAR-T […]